vs
美泰（MAT）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
美泰的季度营收约是Royalty Pharma plc的1.4倍（$862.2M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 7.1%，领先27.4%），Royalty Pharma plc同比增速更快（4.8% vs 4.3%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -10.6%）
美泰是美国知名玩具及娱乐企业，旗下影视制作部门美泰影业运营时间为2018年9月6日至2025年6月2日。其前身为2013年10月16日成立的美泰Playground Productions，更早可追溯至美泰娱乐、美泰工作室等集团原有娱乐业务品牌。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
MAT vs RPRX — 直观对比
营收规模更大
MAT
是对方的1.4倍
$622.0M
营收增速更快
RPRX
高出0.5%
4.3%
净利率更高
RPRX
高出27.4%
7.1%
两年增速更快
RPRX
近两年复合增速
-10.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $862.2M | $622.0M |
| 净利润 | $61.0M | $214.2M |
| 毛利率 | 44.9% | — |
| 营业利润率 | — | 62.4% |
| 净利率 | 7.1% | 34.4% |
| 营收同比 | 4.3% | 4.8% |
| 净利润同比 | 251.4% | 2.9% |
| 每股收益（稀释后） | $0.20 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MATRPRX
| Q1 26 | $862.2M | — | ||
| Q4 25 | $1.8B | $622.0M | ||
| Q3 25 | $1.7B | $609.3M | ||
| Q2 25 | $1.0B | $578.7M | ||
| Q1 25 | $826.6M | $568.2M | ||
| Q4 24 | $1.6B | $593.6M | ||
| Q3 24 | $1.8B | $564.7M | ||
| Q2 24 | $1.1B | $537.3M |
净利润MATRPRX
| Q1 26 | $61.0M | — | ||
| Q4 25 | $106.2M | $214.2M | ||
| Q3 25 | $278.4M | $288.2M | ||
| Q2 25 | $53.4M | $30.2M | ||
| Q1 25 | $-40.3M | $238.3M | ||
| Q4 24 | $140.9M | $208.2M | ||
| Q3 24 | $372.4M | $544.0M | ||
| Q2 24 | $56.9M | $102.0M |
毛利率MATRPRX
| Q1 26 | 44.9% | — | ||
| Q4 25 | 45.9% | — | ||
| Q3 25 | 50.0% | — | ||
| Q2 25 | 50.9% | — | ||
| Q1 25 | 49.4% | — | ||
| Q4 24 | 50.7% | — | ||
| Q3 24 | 53.1% | — | ||
| Q2 24 | 49.2% | — |
营业利润率MATRPRX
| Q1 26 | — | — | ||
| Q4 25 | 8.0% | 62.4% | ||
| Q3 25 | 21.9% | 70.1% | ||
| Q2 25 | 7.7% | 36.3% | ||
| Q1 25 | -6.4% | 94.0% | ||
| Q4 24 | 9.6% | 60.9% | ||
| Q3 24 | 26.5% | — | ||
| Q2 24 | 7.7% | 50.2% |
净利率MATRPRX
| Q1 26 | 7.1% | — | ||
| Q4 25 | 6.0% | 34.4% | ||
| Q3 25 | 16.0% | 47.3% | ||
| Q2 25 | 5.2% | 5.2% | ||
| Q1 25 | -4.9% | 41.9% | ||
| Q4 24 | 8.6% | 35.1% | ||
| Q3 24 | 20.2% | 96.3% | ||
| Q2 24 | 5.3% | 19.0% |
每股收益（稀释后）MATRPRX
| Q1 26 | $0.20 | — | ||
| Q4 25 | $0.32 | $0.49 | ||
| Q3 25 | $0.88 | $0.67 | ||
| Q2 25 | $0.16 | $0.07 | ||
| Q1 25 | $-0.12 | $0.55 | ||
| Q4 24 | $0.40 | $0.46 | ||
| Q3 24 | $1.09 | $1.21 | ||
| Q2 24 | $0.17 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $866.0M | $618.7M |
| 总债务越低越好 | $2.3B | $9.0B |
| 股东权益账面价值 | $2.1B | $9.7B |
| 总资产 | $6.3B | $19.6B |
| 负债/权益比越低杠杆越低 | 1.11× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资MATRPRX
| Q1 26 | $866.0M | — | ||
| Q4 25 | $1.2B | $618.7M | ||
| Q3 25 | $691.9M | $938.9M | ||
| Q2 25 | $870.5M | $631.9M | ||
| Q1 25 | $1.2B | $1.1B | ||
| Q4 24 | $1.4B | $929.0M | ||
| Q3 24 | $723.5M | $950.1M | ||
| Q2 24 | $722.4M | $1.8B |
总债务MATRPRX
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $9.0B | ||
| Q3 25 | $2.3B | $8.9B | ||
| Q2 25 | $2.3B | $8.0B | ||
| Q1 25 | $2.3B | $7.6B | ||
| Q4 24 | $2.3B | $7.6B | ||
| Q3 24 | $2.3B | $7.6B | ||
| Q2 24 | $2.3B | $7.6B |
股东权益MATRPRX
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.2B | $9.7B | ||
| Q3 25 | $2.3B | $9.6B | ||
| Q2 25 | $2.2B | $9.5B | ||
| Q1 25 | $2.1B | $9.8B | ||
| Q4 24 | $2.3B | $10.3B | ||
| Q3 24 | $2.3B | $10.3B | ||
| Q2 24 | $2.0B | $9.8B |
总资产MATRPRX
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.6B | $19.6B | ||
| Q3 25 | $6.6B | $19.3B | ||
| Q2 25 | $6.2B | $18.3B | ||
| Q1 25 | $6.2B | $17.6B | ||
| Q4 24 | $6.5B | $18.2B | ||
| Q3 24 | $6.5B | $18.0B | ||
| Q2 24 | $5.9B | $17.7B |
负债/权益比MATRPRX
| Q1 26 | 1.11× | — | ||
| Q4 25 | 1.04× | 0.92× | ||
| Q3 25 | 1.03× | 0.93× | ||
| Q2 25 | 1.08× | 0.84× | ||
| Q1 25 | 1.10× | 0.78× | ||
| Q4 24 | 1.03× | 0.74× | ||
| Q3 24 | 1.01× | 0.74× | ||
| Q2 24 | 1.18× | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-88.1M | — |
| 自由现金流率自由现金流/营收 | -10.2% | — |
| 资本支出强度资本支出/营收 | 7.6% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MATRPRX
| Q1 26 | — | — | ||
| Q4 25 | $796.6M | $827.1M | ||
| Q3 25 | $72.0M | $702.6M | ||
| Q2 25 | $-300.1M | $364.0M | ||
| Q1 25 | $24.8M | $596.1M | ||
| Q4 24 | $862.1M | $742.5M | ||
| Q3 24 | $155.8M | $703.6M | ||
| Q2 24 | $-252.9M | $658.2M |
自由现金流MATRPRX
| Q1 26 | $-88.1M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
自由现金流率MATRPRX
| Q1 26 | -10.2% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
资本支出强度MATRPRX
| Q1 26 | 7.6% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金转化率MATRPRX
| Q1 26 | — | — | ||
| Q4 25 | 7.50× | 3.86× | ||
| Q3 25 | 0.26× | 2.44× | ||
| Q2 25 | -5.62× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | 6.12× | 3.57× | ||
| Q3 24 | 0.42× | 1.29× | ||
| Q2 24 | -4.45× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MAT
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
